Study of More Than 60,000 Women Underscores Need for Better Understanding
of Implications and Risks Associated with Osteoporosis
MONTREAL, Sept. 15 /CNW/ -- Results from the Global Longitudinal study of
Osteoporosis in Women (GLOW) showed that 55 percent of women diagnosed with
osteoporosis do not believe they are at a higher risk of fractures than their
peers. This latest study from GLOW included more than 60,000 women over age
55 and was presented today at the American Society for Bone and Mineral
Research (ASBMR) 30th Annual Meeting.
"Many women aren't making the connection between their osteoporosis
diagnosis and the serious consequences of the disease, namely the risk of
fractures and the disability associated with those fractures," said Ethel
Siris, M.D., GLOW investigator and Director of the Toni Stabile Osteoporosis
Center of the Columbia University Medical Center, New York-Presbyterian
Hospital, New York, New York. "This study underscores the need for physicians
to help patients better understand the meaning of an osteoporosis diagnosis,
not just from a clinical perspective but also from the perspective of how it
could potentially impact their lives."
By definition, osteoporosis causes bones to become fragile and therefore
more likely to break. If left untreated, the disease can progress painlessly
until a fracture occurs. One in two women over 50 will suffer an osteoporosis
related fracture in their remaining lifetime,(1) potentially causing chronic
pain, reduced mobility, loss of independence and increased risk of death.(2,3)
Results from a second GLOW study also presented at ASBMR indicated that
experiencing even one fracture after the age of 45 years can reduce a woman's
quality of life. This was observed for each of ten different fracture sites
evaluated, namely the spine, ankle, arm, collarbone, hip, pelvis, rib, wrist,
and upper and lower leg.
"Currently osteoporosis remains under-diagnosed and undertreated," said
Cyrus Cooper, M.D., GLOW investigator and Director of the MRC Epidemiology
Resource Centre, University of Southampton, and Norman Collison Chair of
Musculoskeletal Sciences, University of Oxford, United Kingdom. "We hope that
GLOW will highlight the deep impact that a fracture can have on a patient's
life and create an awareness among health professionals that preventive
therapy should be commenced urgently in patients with osteoporotic fractures."
GLOW is a prospective, longitudinal, observational study of women 55
years of age and older who visited a primary care physician during the two
years prior to the study. Over 60,000 women have been recruited through over
700 primary care physicians in 17 cities in the United States, Canada, Europe,
and Australia. GLOW is gathering information on osteoporosis risk factors,
treatment approaches, patient behaviour, and fracture outcomes with an annual
patient survey over a 5 year period.
Self-perceived risk of fracture was assessed using a five-point scale
ranging from "much lower" to "much higher" risk than other women of the same
age. Of 60,112 patients, 11,276 reported an osteoporosis diagnosis.
Data on the occurrence of fracture since the age of 45 years was
collected for 10 skeletal sites (spine, ankle, arm, collarbone, hip, pelvis,
rib, wrist, and upper and lower leg). Fracture history was correlated to a
patient's health-related quality of life as measured by EuroQoL EQ-5D,(4) an
instrument that assesses health in the areas of mobility, self-care, usual
activities of daily living, pain, and depression. The score is expressed as a
health utility score, 1 representing perfect health and 0 representing death.
Patients completing all of the EQ-5D questions (56,866) were included in the
analysis. Mean EQ-5D scores were significantly higher in women with no
fractures versus those with one or multiple fractures since the age of 45
years (0.78 vs. 0.74 and 0.65, respectively). The mean health utility score
ranged from 0.76 for women with wrist fractures to 0.64 for women with spinal
GLOW is supported by an unrestricted educational grant from The Alliance
for Better Bone Health (Procter & Gamble Pharmaceuticals and sanofi-aventis)
and is being directed by The Center for Outcomes Research, University of
Massachusetts Medical School. For more information, visit:
About the Center for Outcomes Research (COR)
COR is based at the University of Massachusetts, Worcester, MA, USA. The
mission of COR is to collect and evaluate data that reflect real world
practices and outcomes and to provide physicians with confidential reports
that allow comparison of their practices to evidence based performance
standards. For more information, please visit: http://www.outcomes.org
(1) National Osteoporosis Foundation. Fast facts. Available at:
http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed August 26, 2008.
(2) Osteoporosis in the European Community: A call to action. Report by
the International Osteoporosis Foundation. (C) Copyright 1999-2007 IOF.
Accessed 06.02.08, available from
(3) Keene GS, Parker MJ & Pryor GA. Mortality and morbidity after hip
fractures. BMJ. 1993 (6914):307;1248-50
(4) EuroQoL Group. EuroQoL -- a new facility for the measurement of
health-related quality of life. Health Policy 1990; 16:199-208.
University of Massachusetts Medical School
For further information:
For further information: United States: Kate Gormley of Dorland Global,
+1-215-928-2720, firstname.lastname@example.org; Europe: Julia O'Brien of Ketchum,
+0044-0-7890-711-037, email@example.com; Canada: Leigha Cotton of Hill
& Knowlton Toronto, +1-416-413-4757, firstname.lastname@example.org, all for
The Alliance for Better Bone Health Web Site: http://www.outcomes.org/glow/